Despite ongoing safety concerns, study finds adverse reactions from contrast agents rarely occur

Sep 21, 2009

Iodinated and Gadolinium based contrast agents, frequently used during computed tomography (CT) and MRI scans to aid in the imaging process, are associated with a very low rate of adverse effects, according to a large cohort study published in the October issue of the American Journal of Roentgenology (AJR).

The study, performed at the Mayo Clinic in Rochester, MN, included a total of 456,930 contrast doses administered. "Only 522 cases of adverse effects were identified," said Christopher H. Hung, MD, lead author of the study. "The overwhelming majority of adverse effects were mild, represented with and and mild rash. Only 16 cases necessitated transfer for further observation and treatment," he said.

"Contrast agents are very safe to use and they are often essential in aiding the diagnosis of CT and MR studies. As our study suggests, with the advent of newer contrast agents we have been able to improve their power-ability and safety profile," said Dr. Hunt.

"While contrast reactions can occur, it is important to note that they are rarely severe. Most of the reactions we saw in our study were mild and did not require treatment other than observation and supportive care," he said.

Source: American Roentgen Ray Society

Explore further: New research demonstrates benefits of national and international device registries

add to favorites email to friend print save as pdf

Related Stories

Allergic-like reactions occur in premedicated patients

Feb 09, 2008

Allergic-like reactions can occur in patients (both children and adults) when given gadolinium containing contrast agents, even if they have been pre-medicated with corticosteroids and antihistamines, according to a recent ...

FDA wants MRI contrast agent warning

May 23, 2007

The U.S. Food and Drug Administration wants a warning printed on the labels of all gadolinium-based magnetic resonance imaging contrast agents.

Recommended for you

New approach to particle therapy dosimetry

16 hours ago

Researchers at the National Physical Laboratory (NPL), in collaboration with EMRP partners, are working towards a universal approach to particle beam therapy dosimetry.

Supplement maker admits lying about ingredients

Dec 17, 2014

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.